Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma

Hepatology Research

Volumn 44, Issue 2, 2014, Pages 194-200

  Tanaka, Masatoshi ^a   Ando, Eiji ^b   Simose, Shigeo ^c   Hori, Maisa ^c   Kuraoka, Kei ^c   Ohno, Miki ^c   Yutani, Shigeru ^c   Harada, Kazunori ^c   Sata, Michio ^d  

^a Yokokura Hospital   (Japan)

^b Iwao Hospital   (Japan)

^c KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Intermediate hepatocellular carcinoma; Radiofrequency ablation; Transarterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; EPIRUBICIN; GELFOAM; IODINATED POPPYSEED OIL; MITOMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; ELECTRODE; FEMALE; FEVER; HEMATOTHORAX; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PAIN; PATIENT CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THORAX DRAINAGE; VERY ELDERLY; VOMITING;

EID: 84893492750     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12100     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
3. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
4. Ebara M, Okabe S, Kita K etal. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43: 458-464.
5. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma< or =4 cm. Gastroenterology 2004; 127: 1714-1723.
6. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661.
7. Shiina S, Teratani T, Obi S etal. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
8. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
9. Goldberg SN, Grassi CJ, Cardella JF etal. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005; 235: 728-739.
10. Sangiovanni A, Del Ninno E, Fasani P etal. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
11. Ando E, Kuromatsu R, Tanaka M etal. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol 2006; 40: 942-948.
12. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
13. Llovet JM, Real MI, Montana X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
14. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
16. Takayasu K, Arii S, Ikai I etal. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
17. Yamakado K, Nakatsuka A, Takaki H etal. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-266.
18. Kagawa T, Koizumi J, Kojima S etal. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 2010; 116: 3638-3644.
19. Helmberger T, Dogan S, Straub G etal. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 2007; 75: 104-112.
20. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16: 661-669.
21. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 2010; 30: 741-749.
22. Kudo M, Chung H, Haji S etal. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
23. Bartolozzi C, Lencioni R, Caramella D etal. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197: 812-818.
24. Koda M, Murawaki Y, Mitsuda A etal. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001; 92: 1516-1524.
25. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6104-6109.
26. Ferrari FS, Stella A, Gambacorta D etal. Treatment of large hepatocellular carcinoma: comparison between techniques and long term results. Radiol Med 2004; 108: 356-371.
27. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res. 2007; 16: 389-397.
28. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther 2008; 25: 787-794.
29. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012; 56: 984-986.